Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• haploidentical patients from maternal or collateral donors

Exclusion Criteria:

• uncontrolled infection before transplant